Free Trial
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$40.61
+1.2%		$45.93
$27.00
▼
$55.67
$6.73B0.322.60 million shs1.63 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$140.58
+6.0%		$92.37
$41.50
▼
$166.48
$5.92B2.831.62 million shs773,590 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$45.28
+4.6%		$52.94
$42.63
▼
$86.74
$7.20B0.384.26 million shs4.86 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$27.26
+3.9%		$30.81
$13.50
▼
$44.60
$1.71B-0.9764,802 shs429,605 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.25%-2.73%-10.55%-21.81%+28.88%
GRAIL, Inc. stock logo
GRAL
GRAIL
+6.01%-1.87%+81.44%+95.25%+93.13%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+4.57%+4.00%-19.17%-22.27%-35.28%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+3.89%-3.67%-15.58%-5.15%+5.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$40.61
+1.2%		$45.93
$27.00
▼
$55.67
$6.73B0.322.60 million shs1.63 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$140.58
+6.0%		$92.37
$41.50
▼
$166.48
$5.92B2.831.62 million shs773,590 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$45.28
+4.6%		$52.94
$42.63
▼
$86.74
$7.20B0.384.26 million shs4.86 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$27.26
+3.9%		$30.81
$13.50
▼
$44.60
$1.71B-0.9764,802 shs429,605 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.25%-2.73%-10.55%-21.81%+28.88%
GRAIL, Inc. stock logo
GRAL
GRAIL
+6.01%-1.87%+81.44%+95.25%+93.13%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
+4.57%+4.00%-19.17%-22.27%-35.28%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+3.89%-3.67%-15.58%-5.15%+5.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.74
Moderate Buy$54.4734.13% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$102.70-26.95% Downside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.73
Moderate Buy$89.2097.00% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$46.7171.37% Upside

Current Analyst Ratings Breakdown

Latest ZBIO, IONS, ALKS, and GRAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$41.00 ➝ $48.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$45.00
9/30/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$85.00
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.67B4.09$1.69 per share23.96$11.02 per share3.69
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M42.67N/AN/A$66.13 per share2.13
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$874.09M8.61N/AN/A$3.02 per share14.99
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M177.68N/AN/A$4.51 per share6.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38106.87169.21N/A3.96%4.15%2.19%10/28/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$3.46N/AN/AN/A-64.76%-111.08%-17.41%11/4/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.99N/AN/AN/AN/A-122.45%-58.04%11/12/2026 (Estimated)

Latest ZBIO, IONS, ALKS, and GRAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.21N/AN/AN/A$183.13 millionN/A
10/28/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0788N/AN/AN/A$463.35 millionN/A
8/12/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.12-$1.77-$0.65-$1.77$15.00 million$1.00 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3.07
7.89
7.73
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.57
9.93
9.93

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1.81%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402166.18 million163.18 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16765.18 million50.84 millionN/A

Recent News About These Companies

Zenas Biopharma Inc (ZBIO)
October 10 at 3:31 AM  |  investing.comhttps://www.investing.com/equities/zenas-biopharma-financial-summary
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis
October 8 at 8:27 PM  |  marketscreener.comM
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis
October 8 at 8:27 PM  |  marketscreener.comM
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.2% - Time to Sell?
October 8 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-shares-down-62-time-to-sell-2026-10-08/
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and ...
October 7 at 6:39 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zenas-biopharma-announces-upcoming-presentations-of-orelabrutinib-data-in-relapsing-remitting-multiple-sclerosis-clinical-trial-designs-in-progressive-multiple-sclerosis-and-other-multiple-1036604494
Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 3.3% - Should You Buy?
October 7 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-stock-jumps-33-should-you-buy-2026-10-07/
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
October 7 at 7:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376353/0/en/zenas-biopharma-announces-upcoming-presentations-of-orelabrutinib-data-in-relapsing-remitting-multiple-sclerosis-clinical-trial-designs-in-progressive-multiple-sclerosis-and-other-.html
Zenas BioPharma to Host Virtual R&D Event on October 27, 2026
October 6, 2026  |  quiverquant.comQ
Zenas BioPharma to Host Virtual R&D Event
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375333/0/en/zenas-biopharma-to-host-virtual-r-d-event.html
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951917-zenas-biopharma-obexelimab-is-being-graded-on-the-wrong-curve-maintain-buy
Zenas BioPharma (NASDAQ:ZBIO) Earns "Outperform" Rating from Wedbush
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077012
HC Wainwright Reaffirms "Buy" Rating for Zenas BioPharma (NASDAQ:ZBIO)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076698
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.1% - Still a Buy?
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-stock-price-up-71-still-a-buy-2026-10-01/
Zenas BioPharma (NASDAQ:ZBIO) Stock Falls 4.5% - Should You Sell?
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073980
Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says
September 30, 2026  |  marketscreener.comM
Wedbush Reaffirms Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO)
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reaffirms-outperform-rating-for-zenas-biopharma-nasdaq-zbio-2026-09-30/
Zenas BioPharma (NASDAQ:ZBIO) Earns Buy Rating from HC Wainwright
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zenas-biopharma-nasdaq-zbio-earns-buy-rating-from-hc-wainwright-2026-09-30/
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950694-zenas-biopharma-inc-zbio-discusses-obexelimab-prelaunch-strategy-and-commercial-opportunity
Transcript : Zenas BioPharma, Inc. - Special Call
September 29, 2026  |  marketscreener.comM
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 4.5% - Here's What Happened
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-shares-down-45-heres-what-happened-2026-09-29/
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 8.2% - Here's Why
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-zenas-biopharma-nasdaq-zbio-trading-down-82-heres-why-2026-09-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Bloom Energy fuel cell units installed outside a data center building labeled "AI" at dusk.
Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
By Thomas Hughes | September 21, 2026
A gold Bitcoin coin sits on a desk in a trading room with large screens displaying market data.
Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
By Nathan Reiff | September 13, 2026
Illustration of the Braze logo at the center of a diagram connecting customer data icons to email, mobile, and messaging channels.
Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
By Nathan Reiff | September 18, 2026
IonQ logo displayed against a dark background with glowing orange network nodes and geometric shapes.
IonQ and NVIDIA Just Cracked a Major Quantum Computing Bottleneck
By Jeffrey Neal Johnson | September 17, 2026
Alkermes stock logo

Alkermes NASDAQ:ALKS

$40.61 +0.50 (+1.25%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$40.64 +0.03 (+0.07%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$140.58 +7.97 (+6.01%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$140.50 -0.08 (-0.06%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$45.28 +1.98 (+4.57%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$45.08 -0.20 (-0.44%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$27.26 +1.02 (+3.89%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$27.26 +0.00 (+0.02%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas